Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

ZIOPHARM Oncology Inc (ZIOP) NPV

Sell:$4.30 Buy:$5.17 Change: $0.07 (1.38%)
NASDAQ:1.00%
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$4.30
Buy:$5.17
Change: $0.07 (1.38%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$4.30
Buy:$5.17
Change: $0.07 (1.38%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Contact details

Address:
One First Avenue Parris Building 34
, Navy Yard Plaza
BOSTON
02129
United States
Telephone:
+1 (617) 2591970
Website:
www.ziopharm.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZIOP
ISIN:
US98973P1012
Market cap:
$957.65 million
Shares in issue:
181.03 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Scott Tarriff
    Chairman, Independent Director
  • David Mauney
    President
  • Laurence Cooper
    Chief Executive Officer, Director
  • Satyavrat Shukla
    Chief Financial Officer, Executive Vice President
  • Robert Hadfield
    Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
  • Lynn Ferrucci
    Executive Vice President - Human Resources, Facilities, Administration and IT
  • Kevin Lafond
    Senior Vice President - Finance, Chief Accounting Officer, Treasurer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.